Prevalence of colorectal cancer in patients with ulcerative colitis: A retrospective, monocenter study in China

被引:62
作者
Zhang, Qin
Sha, Sumei
Xu, Bin
Liang, Shuhui
Wu, Kaichun
机构
[1] Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Shaanxi Provinc, Peoples R China
[2] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xijing Hosp, Xian 710032, Shaanxi Provinc, Peoples R China
基金
中国国家自然科学基金;
关键词
Colorectal cancer; ulcerative colitis; ulcerative colitis-associated colorectal cancer; INFLAMMATORY-BOWEL-DISEASE; COLON-CANCER; FOLLOW-UP; RISK; METAANALYSIS; CARCINOMA; EPIDEMIOLOGY; COHORT; DIAGNOSIS; DYSPLASIA;
D O I
10.4103/0973-1482.143345
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: Ulcerative colitis-associated colorectal cancer (UC-CRC) is a serious complication of UC. Data on the clinical characteristics of patients in China are scarce. Aims: We aimed to study the incidence, characteristics, treatment, and prognosis of CRC patients with a history of UC. Materials and Methods: We identified patients with UC and followed them until the first occurrence of cancer, death, or emigration in a single study center in China. Results: A total of 4 UC-associated CRC patients were identified among the 642 cases recorded from January 2000 to December 2012. The overall risk of cancer was 0.64%. The overall median duration of UC was 15.5 years (range 6-21 years) in patients with UC-associated CRC. Of these patients, 75% (3/4) were at an advanced stage when they were diagnosed. Longer disease duration and extensive colitis were identified as risk factors for developing CRC, and 5-aminosalicylic acid and steroid therapies were not identified as protective factors against UC-associated CRC. Conclusions: Patients with UC are at an increased risk for CRC. However, the prevalence of CRC in China remains lower than that in the West.
引用
收藏
页码:899 / 903
页数:5
相关论文
共 38 条
[1]
[Anonymous], 2013, International Classification of disease for Oncology
[2]
Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? [J].
Bernstein, CN ;
Blanchard, JF ;
Metge, C ;
Yogendran, M .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (12) :2784-2788
[3]
Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO
[4]
2-Z
[5]
C-KI-RAS MUTATIONS IN CHRONIC ULCERATIVE-COLITIS AND SPORADIC COLON-CARCINOMA [J].
BURMER, GC ;
LEVINE, DS ;
KULANDER, BG ;
HAGGITT, RC ;
RUBIN, CE ;
RABINOVITCH, PS .
GASTROENTEROLOGY, 1990, 99 (02) :416-420
[6]
Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis [J].
Castano-Milla, C. ;
Chaparro, M. ;
Gisbert, J. P. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (07) :645-659
[7]
Crohn UB, 1925, AM J MED SCI, V170, P220
[8]
ULCERATIVE COLITIS - EPIDEMIOLOGY AND AETIOLOGY, COURSE AND PROGNOSIS [J].
DEDOMBAL, FT .
BRITISH MEDICAL JOURNAL, 1971, 1 (5750) :649-&
[9]
Colorectal cancer prognosis among patients with inflammatory bowel disease [J].
Delaunoit, T ;
Limburg, PJ ;
Goldberg, RM ;
Lymp, JF ;
Loftus, EV .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (03) :335-342
[10]
Eaden J, 2000, ALIMENT PHARM THERAP, V14, P145